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PURPOSE. To study the clinical involvement of the ocular surface
and the in vivo morphology of corneal cells and nerves, in pa-
tients affected by active and inactive Graves’ orbitopathy (GO).
METHODS. The study included 26 consecutive GO patients and
20 age- and sex-matched healthy control subjects. GO was
diagnosed on the basis of the criteria of the European Group on
Graves’ Orbitopathy, and disease activity was evaluated by the
Clinical Activity Score (CAS). Each participant underwent a full
eye examination, including an evaluation of symptoms (Ocular
Surface Disease Index score), tear break-up time, fluorescein
and lissamine green staining, corneal apex sensitivity, and
Schirmer’s test. The corneal apex was examined by means of
confocal microscopy to investigate the number and morphol-
ogy of epithelial and stromal corneal cells and subbasal nerves.
RESULTS. Eleven (43%) of the 26 patients had active GO. One-
way ANOVA with the least-significant difference (LSD) post
hoc test revealed statistically significant differences between
patients and controls in all the evaluated parameters, except
corneal sensitivity and nerve reflectivity. Among the GO patients,
the only significant difference observed in active compared with
inactive disease was in the number of hyperreflective (activated)
keratocytes (P  0.001, LSD). Corneal sensitivity correlated in-
versely with proptosis (P  0.001, Spearman’s test).
CONCLUSIONS. GO patients show clinical and confocal corneal
alterations and signs and symptoms partially related to dry eye
disease. The ocular surface inflammation in GO seems to be
due to both the dry eye and the autoimmune orbitopathy.
(Invest Ophthalmol Vis Sci. 2010;51:4574–4578) DOI:
10.1167/iovs.10-5380
Graves’ orbitopathy (GO), which in most cases is bilateral,is the most frequent extrathyroidal expression of Graves’
disease.1 Its pathogenesis is thought to be autoimmune.2 The
main risk factors include cigarette smoking, thyroid dysfunc-
tion, and, sometimes, radioiodine therapy for Graves’ hyper-
thyroidism.3
The clinical manifestations of GO reflect the increase in
orbital volume, which may lead to higher intraorbital pressure,
proptosis or exophthalmos, lid retraction, excessive corneal
exposure, diplopia and/or strabismus, soft tissue changes with
periorbital edema, conjunctival hyperemia and chemosis, noc-
turnal lagophthalmos, and the absence of Bell’s phenomenon.1
The alterations of the ocular surface, resulting in both a hypo-
secretory and evaporative mechanism, modifies the tear film
and leads to the development of dry eye syndrome.4
GO is also characterized by various inflammatory signs,
including inflammatory infiltration of the orbital tissues, con-
junctiva and caruncula, which are used to assess its activity by
means of the Clinical Activity Score (CAS)5 and reflect the role
of inflammation in the pathogenesis of dry eye.1,6
Confocal microscopy is a rapid and noninvasive technique
that enables examination of the different layers of the cornea in
vivo (cells and nerve fibers) and detection of possible alter-
ations. Some of these have been recently interpreted as signs of
inflammatory activity7: The presence of Langerhans’ cells in
subepithelial infiltrates after epidemic keratoconjunctivitis has
been shown to be related to immunologically mediated re-
sponse,8 and epithelial dendritic cells have been reported to be
modified in immune-mediated inflammation, such as graft re-
jection and recurrent herpetic keratitis.9 The number of bead-
like formations (in herpetic keratitis and rheumatoid arthri-
tis),10,11 and the number of activated keratocytes (in rheumatoid
arthritis and Sjo¨gren’s syndrome)11,12 have been interpreted as
confocal signs of ocular surface disease activity.
The purpose of this study was to analyze clinical and con-
focal changes in the ocular surface of patients with active and
inactive GO.
METHODS
Patients
We consecutively recruited 26 patients (8 men and 18 women; mean
age, 50.75  16.82 years; range, 29–75), who had a diagnosis of GO
based on the criteria of the European Group on Graves’ Orbitopathy
(EUGOGO) Consensus Statement.5,13 All the patients were recruited at
the EUGOGO Center of the Fondazione IRCCS Ospedale Maggiore
Policlinico, Mangiagalli e Regina Elena, Milan, Italy. GO activity was
defined by using the CAS,14 which was assigned after each patient’s
examination by an ophthalmologist and endocrinologist. This score is
based on four well-known classic signs of inflammation (pain, redness,
swelling, and impaired function) and consists of 10 items. For each
sign that is present, one point is given. Each sign has the same weight.
The sum of these points is the CAS (range, 0–10).14
The control group consisted of 20 healthy subjects (7 men and 13
women; mean age, 51.20  18.20 years; range, 27–76) affiliated with
our general clinic.
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Patients with lymphomas, AIDS, sarcoidosis, diabetes mellitus, or
corneal dystrophy; those in treatment with systemic corneotoxic drugs
or having local treatments with anti-glaucoma or steroidal or non-
steroidal anti-inflammatory drugs (NSAIDs); and those wearing contact
lenses or having undergone ophthalmic surgery were excluded from
the study.
All subjects gave their written informed consent for participation in
the study, which was conducted in accordance with the guidelines of
the Declaration of Helsinki and the Italian privacy law.
Clinical Evaluation
The medical history of each participant was carefully recorded.
Any subjective symptoms of a disease affecting the ocular surface
and their impact on visual function were evaluated according to the
standardized Ocular Surface Disease Index (OSDI), and the score was
calculated.15
All subjects underwent a thorough ophthalmic examination of both
eyes, including a biomicroscopic examination of the ocular adnexa and
anterior segment. The cornea was stained with sodium fluorescein
1% collyrium, and the tear film break-up time (BUT) was quantified
with cobalt blue light; corneal staining was assessed with the CLEK
schema,16 with the cornea divided into five areas. Subsequently, the
conjunctiva was stained with lissamine green and analyzed with the
CLEK schema16 in four areas. The staining scale was 0 to 4, with 0.5
unit steps in each region. Photographs were used as examples of
severity. Corneal sensitivity was evaluated with a Cochet-Bonnet nylon-
thread esthesiometer. Finally, Schirmer’s test was performed after
application of topical anesthesia (oxybuprocaine chloride 0.4%).
Confocal Microscopy
Image Acquisition. After a drop of the anesthetic had been
instilled in the lower conjunctival fornix, the corneal apex was exam-
ined by confocal microscope (Confoscan 3.0; Nidek Technologies,
Vigonza, Italy) equipped with a standard 40 objective. During the
examination, the objective lens of the microscope was covered with
gel (hydroxypropylmethyl cellulose 0.3%, Carbopol 980; Noveon Eu-
rope, Brussels, Belgium, or Dequest 2060S; Solutia, St. Louis, MO) and
never came into direct contact with the corneal surface. A drop of
antibiotic (ofloxacin 0.3%) was instilled in the lower conjunctival
fornix at the end of each examination, and the eye was re-examined by
means of a slit lamp to verify the integrity of the corneal surface.
The full thickness of the cornea was scanned automatically for 2 to
3 minutes. Each scan recorded 350 z-axis images separated by a
distance of 1.5 m, making two to four complete passages from the
lacrimal film to the anterior chamber. Each frame covered an area of
approximately 440  330 m.
Image Analysis. Z-scan curves (graphs showing the depth
coordinate on the z-axis and the level of reflectivity on the y-axis)17
were used to select the images relating to the superficial and basal
epithelium, the anterior and posterior stroma, and Bowman’s mem-
brane or the subbasal epithelium. This method made it possible to
evaluate the cell density of the superficial and basal epithelium, and
the apparent cell density of the anterior and posterior stroma,
concentrating particularly on the number of highly reflective (acti-
vated) keratocytes.
Cell density was determined with a manual cell counting procedure
in the software, considering the entire area marked as available. Any
cells partially contained in the analyzed area were only counted along
the right and lower margins. The results are expressed as the number
of cells per square millimeter.
The cell densities, obtained by a second independent investigator,
were used to calculate the K-value to assess interobserver agreement.
The image of the subbasal plexus containing the largest number of
recognizable nerve fibers was selected for each scan. Corneal innerva-
tion was studied by considering the number of nerves, the degree of
tortuosity and fiber reflectivity graded 0 to 4 after comparison with the
reference images, as suggested by Oliveira-Soto and Efron.18 The num-
ber of beadlike formations per 100 m of nerve fiber was counted as
described by Benitez del Castillo et al.19
TABLE 1. Clinical Data: Systemic Pathology and Orbitopathy
Inactive GO Active GO P*
GO
Time since symptom onset, mo 40.25  57.13 16.81  8.24 0.139
Time since diagnosis, mo 34.00  56.49 14.27  9.26 0.203
CAS 0.93  0.79 3.72  0.90 0.001
Proptosis, mm
RE 21.56  3.88 23.27  2.64 0.196
LE 22.10  3.71 23.04  2.74 0.463
TSH, mU/L 1.11  1.14 2.37  2.64 0.166
FT4, pmol/L 3.95  3.71 5.93  6.14 0.369
FT3, pmol/L 4.39  3.35 5.23  2.09 0.455
* t-Test.
TABLE 2. Clinical Data for the Ocular Surface
Inactive GO Active GO Control Subjects P*
Age, y 46.26  10.51 56.63  9.98 51.20  18.20 NS
OSDI score 22.01  17.39 29.13  12.48 0.53  0.54 0.001†
BUT, s 6.64  2.23 6.45  3.07 10.36  1.85 0.001‡
Fluorescein staining, total score 1.14  1.16 0.90  0.30 NS
Lissamine green staining, total score 0.71  0.61 1.09  1.22 NS
Corneal sensitivity 5.67  0.42 5.43  0.822 5.85  0.39 0.12
Schirmer’s test, mm 9.84  2.96 9.54  2.91 15.03  3.51 0.001§
* ANOVA.
† Inactive GO, active GO vs. control; P  0.001, LSD. Inactive GO vs. active GO; P  0.13, LSD.
‡ Inactive GO, active GO vs. control; P  0.001, LSD. Inactive GO vs. active GO; P  0.84, LSD.
§ Inactive GO, active GO vs. control; P  0.001, LSD. Inactive GO vs. active GO; P  0.821, LSD.
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Statistical Analysis
The data for the worse eye of each subject—that is, the eye with the
highest fluorescein staining score—were included in the analysis. In
the case of equal scores for the two eyes, the sequential discriminating
criteria were the lower Schirmer’s test score and the lower BUT score.
All the data are expressed as the mean  SD. The normal distribu-
tion of the variables was verified using the Kolmogorov-Smirnov test.
One-way ANOVA with the LSD post hoc test was used to compare the
mean scores of the control subjects and patients with active or inactive
GO and the t-test for independent samples to compare the GO clinical
data (active GO versus inactive GO). The correlations between the
variables were evaluated by using Spearman’s index of linear correla-
tion. P  0.05 was considered significant (SPSS for Windows, ver. 9.0;
SPSS Sciences, Chicago, IL).
RESULTS
Patients’ Clinical Data
Eleven patients had active GO (43%; 2 men and 9 women;
mean age, 56.63  9.98 years; range, 42–75), and 15 had
inactive GO (57%; 6 men and 9 women; mean age, 46.26 
10.51 years; range, 29–67). CAS was significantly higher in
active compared with inactive GO (P  0.001, t-test); there
were no other significant differences in the systemic clinical
data in patients with active versus inactive GO (Table 1).
Clinical Data: Ocular Surface
The OSDI score was significantly higher in GO patients than in
the control subjects, and BUT and Schirmer’s test values were
significantly reduced (P  0.001, LSD). No differences were
found between the two GO groups (Table 2).
Confocal Microscopy Data
Cell Density. Cell density in the different layers was signif-
icantly different between the GO patients and the control
subjects (superficial epithelium and anterior stroma: P 
0.001, LSD; basal epithelium and posterior stroma: P  0.05,
LSD), but there were no significant differences between the
patients with active or inactive GO. However, the density of
activated keratocytes (Fig. 1) was significantly different be-
tween the patient groups (P  0.001, LSD; Table 3).
There was substantial agreement between the two investi-
gators in relation to all these variables: K  0.75 (superficial
epithelium), 0.96 (basal epithelium), 0.78 (anterior stroma),
0.80 (posterior stroma), and 0.66 (activated keratocytes).
Innervation Data. A comparison of GO patients with con-
trols showed a lower number of nerve fibers and an increased
degree of tortuosity and number of beadlike formations (Fig. 2;
P  0.001, LSD; Table 4).
Correlations
There were positive correlations between FT3 and FT4 levels
and disease activity (P  0.05, Spearman) and between the
onset of symptoms and diagnosis and the degree of proptosis
(P  0.05, Spearman). There was a significant inverse correla-
tion between sensitivity at the corneal apex and proptosis (P
0.001, Spearman). No significant correlations were found be-
tween confocal and clinical data.
DISCUSSION
GO is the most frequent extrathyroidal expression of Graves’
disease and has various ocular manifestations.1 Its onset appar-
ently peaks bimodally in the fifth and seventh decades of life,
but eye disease may occur at any age.20
The natural history of GO is not completely understood, but
it is generally agreed that it has an initial active phase charac-
terized by the progressive exacerbation of ocular manifesta-
tions and then tends to remit spontaneously, although the
remission is invariably partial.21
FIGURE 1. Confocal stromal images
showing several activated kerato-
cytes in a GO patient (A) and no
activated keratocytes in a control
subject (B).
TABLE 3. Cell Density Data from Confocal Microscopy
Inactive GO Active GO Control Subjects P*
Superficial epithelium, cells/mm2 1033.20  168.30 1011.36  199.36 1517.15  130.65 0.001†
Basal epithelium, cells/mm2 5816.26  209.69 5806.81  240.09 5600.95  235.94 0.05‡
Anterior stroma, cells/mm2 1189.46  89.24 1215.81  88.71 971.15  103.56 0.001§
Posterior stroma, cells/mm2 809.33  120.01 787.72  116.85 719.10  78.42 0.05
Activated keratocytes, cells/frame 3.41  1.49 6.04  2.93 0.42  0.73 0.001¶
* ANOVA.
† Inactive GO, active GO vs. control; P  0.001, LSD. Inactive GO vs. active GO; P  0.735, LSD.
‡ Inactive GO, active GO vs. control; P  0.05, LSD. Inactive GO vs. active GO; P  0.918, LSD.
§ Inactive GO, active GO vs. control; P  0.001, LSD. Inactive GO vs. active GO; P  0.492, LSD.
 Inactive GO vs. active GO; P  0.599, LSD. Inactive GO vs. control; P  0.05, LSD. Active GO vs. control; P  0.083, LSD.
¶ Inactive GO, active GO vs. control; P  0.001, LSD. Inactive GO vs. active GO; P  0.001, LSD.
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The degree of proptosis in our patients was greater than
that observed in previous studies of thyroid orbitopathy.22–25 It
correlated with the onset of symptoms and diagnosis and was
probably due to greater severity.
All GO patients had signs and symptoms characteristic of
dry eye.26 The OSDI scores of the GO patients and control
subjects were significantly different, but the slight difference
between the patients with active or inactive disease was not
statistically significant. There was no significant correlation
between the OSDI and Schirmer’s type 1 test, tear BUT, or
fluorescein or lissamine green staining, which is not surprising
in patients with dry eye.27
The Schirmer test results were significantly different be-
tween the patients and controls but, although the patients’
results (6–13 mm) suggested mild lacrimal hyposecretion,24
they did not explain the entire ocular surface disease. Tear BUT
was significantly shorter in the patients, suggesting an unstable
tear film. This finding was consistent with those of patients
with long-standing GO23,25 but was higher than those reported
in patients with active thyroid-associated orbitopathy.24,28 Tear
film instability is considered to be one of the core mechanisms
involved in dry eye.4
Ocular surface fluorescein and lissamine green staining was
surprisingly poor. The results were similar only to the data on
corneal staining reported by Khurana et al.,23 whereas most
research groups have reported greater corneal and conjuncti-
val staining,22,24,28 including Gupta et al.,29 who reported that
fluorescein staining of the cornea is the most common finding
due to ocular surface inflammation in occult thyroid eye dis-
ease. However, a fluorescein staining score of 1 is the most
frequent in GO,30 and higher scores have been recorded in
only a very small samples of patients.30,31
The corneal sensitivity was only partially reduced in pa-
tients compared with control subjects. The difference was not
statistically significant, and the reduction was not as great as in
other types of dry eye.11,12,32 This result may explain the mild
lacrimal hyposecretion revealed by Schirmer’s test, which may
be caused by both active inflammation and stimulation of
lacrimal TSH receptors by Graves autoantibodies demonstrated
by Eckstein et al.24
The dry eye associated with GO therefore seems to be
mainly evaporative, due to increased corneal exposure. Ac-
cording to Gupta et al.,29 patients with GO do not generally
show poor aqueous production but, based on our Schirmer test
results and the presence of inflammation, we believe that a
hyposecretory component cannot be excluded and may con-
tribute to both GO and dry eye syndrome, as also suggested by
Eckstein et al.24
Over the past few years, confocal microscopy has provided
new opportunities of studying the in vivo structure of the
cornea. As in other recent studies,11,12,19 we used it to make a
quantitative evaluation of corneal alterations, a major evolution
in the application of this technology. The observed morpho-
logic changes are similar to those recently described in various
types of dry eye.11,12,19
The significant reduction in surface epithelial cell density in
our GO patients was probably due to the damaged ocular
surface caused by typical exophthalmos, lid retraction, noctur-
nal lagophthalmos, and the absence of Bell’s phenomenon. On
the contrary, the increased number of basal epithelium cells in
GO patients may be caused by the proliferative stimulus in-
duced in dry eye by superficial desiccating stress, as was
demonstrated by Fabiani et al.33
The increased stromal cell density may be the result of the
inflammatory process itself, which involves the ocular surface
and causes a synchronous increase in stromal apoptotic phe-
nomena, proteolytic activity, and proliferating stimuli.12
As previously observed by Tuominen,34 Villani et al.,11 and
Benitez del Castillo19 in different studies, the increased stromal
cell density was accompanied by hyperreflective, activated
keratocytes. These may be regarded as inflammatory cells that
are in a specific stage of metabolic activation induced by
proinflammatory cytokines such as IL-1 and -611 and are capa-
FIGURE 2. Confocal image showing
subbasal nerve fibers (A), with evident
beadlike formations (B, arrows).
TABLE 4. Innervation: Confocal Microscopy
Inactive GO Active GO Control Subjects P*
Nerves, n 3.29  1.13 3.28  1.21 5.04  0.83 0.001†
Tortuosity 2.49  0.91 2.58  0.96 1.33  0.64 0.001‡
Reflectivity 1.73  1.27 2.60  1.40 2.02  1.02 0.194
Beadlike formations, n 311.25  67.89 345.61  65.24 201.55  70.28 0.001§
* ANOVA.
† Inactive GO, active GO vs. control; P  0.001, LSD. Inactive GO vs. active GO; P  0.976, LSD.
‡ Inactive GO, active GO vs. control; P  0.001, LSD. Inactive GO vs. active GO; P  0.78, LSD.
§ Inactive GO, active GO vs. control; P  0.001, LSD. Inactive GO vs. active GO; P  0.212, LSD.
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ble of producing proinflammatory cytokines such as nerve
growth factor.12
Another largely reported confocal sign of inflammation is
the number of dendritic cells.9 These cells, which may be
interpreted as antigen-presenting cells, are clearly detectable by
laser scanning confocal microscopy. In our experience, the
white-light confocal microscope used in this study is more
effective for analyzing the stroma but less useful for studying
the subbasal dendritic cells. Therefore, we preferred not to use
this variable to quantify inflammation.
It is important to note that the number of activated kerato-
cytes was the only sign that was found to be significantly
different when GO patients were compared to control subjects
and also when active GO was compared to inactive GO. This
result suggests that patients with active GO not only show
more diffuse inflammation at the level of the ocular adnexa (as
quantified by CAS), but are also more affected by corneal
inflammation.
In GO patients, the number of nerves was reduced, and the
tortuosity of the nerve fiber and the number of beadlike for-
mations were increased, as was found in other studies of dry
eye.11,19,35 This sign may not be specific for dry eye, but an
indication of metabolic activation of the plexus35 related to the
systemic disease (the NGF secreted by keratocytes makes a
substantial contribution to this activation).
In conclusion, confocal microscopy is extremely useful for
quantitatively evaluating ocular surface inflammation. It also
provides a very interesting opportunity for future studies of
ocular surface disease activity that integrate traditional clinical
data (such as CAS) and new, rapid, and noninvasive methods of
investigating in vivo tissue histology.
The ocular surface of GO patients seems to be simulta-
neously affected by two inflammatory processes: one second-
ary to dry eye and the other related to the systemic disease
itself.
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